GO
Loading...

A spec play with a potential healthy boost

Friday, 27 Sep 2013 | 6:25 PM ET

This week, three firms initiated coverage on speculative development stage biotech company Pharmacyclics. Mad Money host Jim Cramer reveals the risks with this spec play.